The "text only" version in this language is not currently available.
Misoprostol for the Treatment of Postpartum Hemorrhage: Findings from Clinical Research Trials
This research summary describes the results of a series of clinical trials conducted by Gynuity and international colleagues on the use of misoprostol for the treatment of postpartum hemorrhage. The findings show:
- Sublingual misoprostol (800 mcg) is a safe, effective and acceptable alternative first-line treatment for PPH due to uterine atony.
- Misoprostol is easy to administer and may be particularly useful in settings where administration of IV oxytocin is not possible, particularly at lower levels of the health care system.
- Simultaneous administration of misoprostol (600 mcg) to conventional uterotonics for PPH treatment confers no clinical advantage.